granzyme B Antibody (GRB7): sc-73620
- granzyme B Antibody (GRB7) is a mouse monoclonal IgG2a, cited in 2 publications, provided at 50 µg/0.5 ml
- raised against full length granzyme B of human origin
- recommended for detection of granzyme B of human origin by WB, IP, IF and IHC(P)
- See granzyme B (2C5): sc-8022 for granzyme B antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for granzyme B Antibody (GRB7). This work is in progress.
QUICK LINKS
SEE ALSO...
Granzyme B Antibody (GRB7) is a mouse monoclonal IgG2a antibody that detects granzyme B of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. Anti-granzyme B antibody (GRB7) is available in a non-conjugated form, allowing for versatile applications in various experimental settings. Granzyme B plays a crucial role in the immune response, particularly in the induction of apoptosis in target cells, which is essential for maintaining immune homeostasis and eliminating infected or malignant cells. This serine protease is primarily located within cytolytic granules of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells, where granzyme B is stored as an inactive proenzyme until release during the degranulation process. Upon activation, granzyme B cleaves and activates caspases, such as caspase-3, caspase-6, caspase-7, and caspase-9, leading to a cascade of events that culminate in programmed cell death. The precise localization of granzyme B within cytolytic granules is vital, as this ensures direct delivery to target cells during immune responses, thereby enhancing the efficiency of apoptosis induction. Understanding the function and localization of granzyme B is critical for developing therapeutic strategies aimed at modulating immune responses in various diseases, including cancer and autoimmune disorders.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
granzyme B Antibody (GRB7) References:
- Human Granzyme B Based Targeted Cytolytic Fusion Proteins. | Hlongwane, P., et al. 2018. Biomedicines. 6: PMID: 29925790
- Granzyme B production by activated B cells derived from breast cancer-draining lymph nodes. | Arabpour, M., et al. 2019. Mol Immunol. 114: 172-178. PMID: 31357083
- Granzyme B Attenuates Bacterial Virulence by Targeting Secreted Factors. | León, DL., et al. 2020. iScience. 23: 100932. PMID: 32151975
- Granzyme B in Inflammatory Diseases: Apoptosis, Inflammation, Extracellular Matrix Remodeling, Epithelial-to-Mesenchymal Transition and Fibrosis. | Velotti, F., et al. 2020. Front Immunol. 11: 587581. PMID: 33262766
- Granzyme B inhibition reduces disease severity in autoimmune blistering diseases. | Hiroyasu, S., et al. 2021. Nat Commun. 12: 302. PMID: 33436591
- Interaction Networks Converging on Immunosuppressive Roles of Granzyme B: Special Niches Within the Tumor Microenvironment. | Wang, W., et al. 2021. Front Immunol. 12: 670324. PMID: 33868318
- Impaired granzyme B-producing regulatory B cells in systemic lupus erythematosus. | Bai, M., et al. 2021. Mol Immunol. 140: 217-224. PMID: 34749262
- Murine regulatory T cells utilize granzyme B to promote tumor metastasis. | Tibbs, E., et al. 2023. Cancer Immunol Immunother. 72: 2927-2937. PMID: 36826509
- Granzyme B May Act as an Effector Molecule to Control the Inflammatory Process in COPD. | Kim, WD. and Sin, DD. 2024. COPD. 21: 1-11. PMID: 38314671
- Granzyme B PET Imaging for Assessment of Disease Activity in Inflammatory Bowel Disease. | Heidari, P., et al. 2024. J Nucl Med. 65: 1137-1143. PMID: 38754959
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
granzyme B Antibody (GRB7) | sc-73620 | 50 µg/0.5 ml | $316.00 |